10-Q quarterly report · filed Oct 30, 2026

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2026 10-Q Quarterly Report

Short answer

Aurinia Pharmaceuticals Inc. (AUPH) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (up 13.9% year over year) with net income of $32M.

Q3 2026 key financials · XBRL

Revenue
$84M
+13.9% YoY · +0.6% QoQ
Net income
$32M
+0.5% YoY · −15.3% QoQ
Operating margin
42.3%
EPS (diluted)
$0.23
+0.0% YoY · −17.9% QoQ

Source: XBRL data from the Aurinia Pharmaceuticals Inc. (AUPH) Q3 2026 10-Q on SEC EDGAR. USD.

Aurinia Pharmaceuticals Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $83.7M, up 14% YoY from $73.5M, driven by LUPKYNIS sales
  • Gross margin 90% vs 89% YoY, net income $31.7M vs $31.6M
  • LUPKYNIS sales $79.4M, up 12% YoY from $70.6M
  • Cash, restricted cash and investments $486.9M vs $398.0M at December 31, 2025
  • Operating cash flow $131.5M, up 46% YoY; share repurchases $74.9M for 5.0M shares

Risk Factors

  • No material risk-factor changes since the December 31, 2025 Form 10-K
  • Carried-forward financial-performance risks could cause actual results to differ materially from expectations
  • Additional currently immaterial or unknown risks could materially affect future results

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Aurinia Pharmaceuticals Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.